Last reviewed · How we verify
rituximab+chlorambucil
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while chlorambucil is an alkylating agent that interferes with DNA replication.
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while chlorambucil is an alkylating agent that interferes with DNA replication. Used for Follicular lymphoma, Mantle cell lymphoma.
At a glance
| Generic name | rituximab+chlorambucil |
|---|---|
| Sponsor | International Extranodal Lymphoma Study Group (IELSG) |
| Drug class | Monoclonal antibody + alkylating agent |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Rituximab works by binding to the CD20 antigen on the surface of B cells, marking them for destruction by the immune system. Chlorambucil, on the other hand, damages the DNA of rapidly dividing cells, including cancer cells, thereby inhibiting their growth and proliferation.
Approved indications
- Follicular lymphoma
- Mantle cell lymphoma
Common side effects
- Infusion-related reactions
- Neutropenia
- Thrombocytopenia
- Anemia
- Infections
Key clinical trials
- Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma (PHASE2)
- A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL. (PHASE3)
- ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL (PHASE3)
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia (PHASE1)
- A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (PHASE2)
- Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma (PHASE3)
- Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rituximab+chlorambucil CI brief — competitive landscape report
- rituximab+chlorambucil updates RSS · CI watch RSS
- International Extranodal Lymphoma Study Group (IELSG) portfolio CI